<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459106</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMDFH 729828</org_study_id>
    <nct_id>NCT02459106</nct_id>
  </id_info>
  <brief_title>Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans</brief_title>
  <acronym>miRNA</acronym>
  <official_title>Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is examine the effect of fat tissue-released miRNA on skeletal
      muscle and if abnormal fat tissue-released miRNA contributes to insulin resistance in obese
      individuals. This information will be important for our understanding of how the body's sugar
      metabolism is regulated and why people who are obese become insulin resistant and are more
      likely to develop type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:

        1. To establish and optimize the methodology for measuring adipose tissue miRNA release.

        2. To establish and optimize the methodology for measuring the effect of adipose
           tissue-released miRNA on skeletal muscle biology and insulin sensitivity.

        3. To profile adipose tissue-released miRNA in lean insulin-sensitive and obese
           insulin-resistant healthy individuals.

        4. To examine the effects of adipose tissue-released miRNA from lean insulin-sensitive
           individuals and obese insulin-resistant individuals on skeletal muscle biology and
           insulin sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of miRNA will be measured as well as the adipose tissue specific miRNA.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The effect of miRNA released by adipose tissue from lean insulin-sensitive and from obese insulin-resistant individuals on skeletal muscle biology and insulin signaling.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Healthy lean insulin-sensitive individuals</arm_group_label>
    <description>This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese insulin-resistant individuals</arm_group_label>
    <description>This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Muscle and adipose tissue biopsies will be obtained.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy obese insulin-resistant individuals Healthy lean insulin-sensitive individuals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to communicate meaningfully with the investigator and legally competent to
             provide informed written consent

          -  18-65 years of age

          -  BMI of 20-25 kg/m2 (lean subjects); 30-35 kg/m2 (obese subjects)

          -  Stable body weight (&lt; 3 kg change in the last 8 weeks)

          -  homeostatic model assessment (HOMA)-insulin resistance &lt;2.7 if lean; homeostatic model
             assessment (HOMA)-insulin resistance ≥2.7 if obese

        Exclusion Criteria:

          -  Lactation or pregnancy, current and/or within last 6 months, per participant's report

          -  Female subjects postmenopausal

          -  Cardiovascular disease (unstable angina, myocardial infarction or coronary
             revascularization within 6 months)

          -  Liver disease (AST or ALT(alanine aminotransferase)&gt;2.5 times the upper limit of
             normal)

          -  Kidney disease (creatinine &gt;1.6 mg/dl)

          -  Anemia (hemoglobin &lt;12 g/dl in men, &lt;11 g/dl in women)

          -  Thyroid dysfunction (abnormal TSH)

          -  HbA1c ≥6.5%

          -  Uncontrolled hypertension (systolic BP&gt;160 mmHg, diastolic BP&gt;100 mmHg)

          -  History of coagulopathies

          -  History (within the last 5 years) or presence of malignancy, (skin cancers, with the
             exception of melanoma, may be acceptable)

          -  Current or history of drug abuse or alcohol abuse (&gt;2 drinks/day)

          -  Prior treatment (within last 3 months) with systemic glucocorticoids (&gt;2 weeks),
             beta-blockers, drugs for weight loss, niacin or fibrates

          -  History of HIV, active Hepatitis B or C, or Tuberculosis (participant reported)

          -  Smoke &gt; 5 cigarettes per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Pratley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Research Institute for Metabolism and Diabetes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org</url>
    <description>Florida Hospital's Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res. 1994 Feb;35(2):177-93. Review.</citation>
    <PMID>8169522</PMID>
  </reference>
  <reference>
    <citation>Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand. 2005 Aug;184(4):285-93. Review.</citation>
    <PMID>16026420</PMID>
  </reference>
  <reference>
    <citation>Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004 Jan 23;116(2):337-50. Review.</citation>
    <PMID>14744442</PMID>
  </reference>
  <reference>
    <citation>Xie H, Sun L, Lodish HF. Targeting microRNAs in obesity. Expert Opin Ther Targets. 2009 Oct;13(10):1227-38. doi: 10.1517/14728220903190707. Review.</citation>
    <PMID>19650761</PMID>
  </reference>
  <reference>
    <citation>Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, Ailhaud G, Dani C, Amri EZ, Scheideler M. microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun. 2009 Dec 11;390(2):247-51. doi: 10.1016/j.bbrc.2009.09.098. Epub 2009 Oct 2.</citation>
    <PMID>19800867</PMID>
  </reference>
  <reference>
    <citation>Kim SY, Kim AY, Lee HW, Son YH, Lee GY, Lee JW, Lee YS, Kim JB. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem Biophys Res Commun. 2010 Feb 12;392(3):323-8. doi: 10.1016/j.bbrc.2010.01.012. Epub 2010 Jan 7.</citation>
    <PMID>20060380</PMID>
  </reference>
  <reference>
    <citation>Ortega FJ, Moreno-Navarrete JM, Pardo G, Sabater M, Hummel M, Ferrer A, Rodriguez-Hermosa JI, Ruiz B, Ricart W, Peral B, Fernández-Real JM. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS One. 2010 Feb 2;5(2):e9022. doi: 10.1371/journal.pone.0009022.</citation>
    <PMID>20126310</PMID>
  </reference>
  <reference>
    <citation>Sun L, Xie H, Mori MA, Alexander R, Yuan B, Hattangadi SM, Liu Q, Kahn CR, Lodish HF. Mir193b-365 is essential for brown fat differentiation. Nat Cell Biol. 2011 Jul 10;13(8):958-65. doi: 10.1038/ncb2286.</citation>
    <PMID>21743466</PMID>
  </reference>
  <reference>
    <citation>Zaragosi LE, Wdziekonski B, Brigand KL, Villageois P, Mari B, Waldmann R, Dani C, Barbry P. Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol. 2011 Jul 18;12(7):R64. doi: 10.1186/gb-2011-12-7-r64.</citation>
    <PMID>21767385</PMID>
  </reference>
  <reference>
    <citation>Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia. 2013 Sep;56(9):1971-9. doi: 10.1007/s00125-013-2950-9. Epub 2013 Jun 12.</citation>
    <PMID>23756832</PMID>
  </reference>
  <reference>
    <citation>Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000 Nov 2;408(6808):86-9.</citation>
    <PMID>11081512</PMID>
  </reference>
  <reference>
    <citation>Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001 Oct 26;294(5543):853-8.</citation>
    <PMID>11679670</PMID>
  </reference>
  <reference>
    <citation>Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001 Oct 26;294(5543):862-4.</citation>
    <PMID>11679672</PMID>
  </reference>
  <reference>
    <citation>Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001 Oct 26;294(5543):858-62.</citation>
    <PMID>11679671</PMID>
  </reference>
  <reference>
    <citation>Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008 Feb;9(2):102-14. doi: 10.1038/nrg2290. Review.</citation>
    <PMID>18197166</PMID>
  </reference>
  <reference>
    <citation>Martinelli R, Nardelli C, Pilone V, Buonomo T, Liguori R, Castanò I, Buono P, Masone S, Persico G, Forestieri P, Pastore L, Sacchetti L. miR-519d overexpression is associated with human obesity. Obesity (Silver Spring). 2010 Nov;18(11):2170-6. doi: 10.1038/oby.2009.474. Epub 2010 Jan 7.</citation>
    <PMID>20057369</PMID>
  </reference>
  <reference>
    <citation>Klöting N, Berthold S, Kovacs P, Schön MR, Fasshauer M, Ruschke K, Stumvoll M, Blüher M. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS One. 2009;4(3):e4699. doi: 10.1371/journal.pone.0004699. Epub 2009 Mar 4.</citation>
    <PMID>19259271</PMID>
  </reference>
  <reference>
    <citation>Herrera BM, Lockstone HE, Taylor JM, Ria M, Barrett A, Collins S, Kaisaki P, Argoud K, Fernandez C, Travers ME, Grew JP, Randall JC, Gloyn AL, Gauguier D, McCarthy MI, Lindgren CM. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia. 2010 Jun;53(6):1099-109. doi: 10.1007/s00125-010-1667-2. Epub 2010 Mar 3.</citation>
    <PMID>20198361</PMID>
  </reference>
  <reference>
    <citation>Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes. 2009 May;58(5):1050-7. doi: 10.2337/db08-1299. Epub 2009 Feb 2.</citation>
    <PMID>19188425</PMID>
  </reference>
  <reference>
    <citation>Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. Circulating miRNAs: cell-cell communication function? Front Genet. 2013 Jun 28;4:119. doi: 10.3389/fgene.2013.00119. Print 2013.</citation>
    <PMID>23825476</PMID>
  </reference>
  <reference>
    <citation>Ogawa R, Tanaka C, Sato M, Nagasaki H, Sugimura K, Okumura K, Nakagawa Y, Aoki N. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem Biophys Res Commun. 2010 Aug 6;398(4):723-9. doi: 10.1016/j.bbrc.2010.07.008. Epub 2010 Jul 17.</citation>
    <PMID>20621060</PMID>
  </reference>
  <reference>
    <citation>Deng ZB, Poliakov A, Hardy RW, Clements R, Liu C, Liu Y, Wang J, Xiang X, Zhang S, Zhuang X, Shah SV, Sun D, Michalek S, Grizzle WE, Garvey T, Mobley J, Zhang HG. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes. 2009 Nov;58(11):2498-505. doi: 10.2337/db09-0216. Epub 2009 Aug 12.</citation>
    <PMID>19675137</PMID>
  </reference>
  <reference>
    <citation>Dietze D, Koenen M, Röhrig K, Horikoshi H, Hauner H, Eckel J. Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes. 2002 Aug;51(8):2369-76.</citation>
    <PMID>12145147</PMID>
  </reference>
  <reference>
    <citation>Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes. 2005 Jul;54(7):2003-11.</citation>
    <PMID>15983200</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2015</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>micro-RNA</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

